ArticleJournal of the neurological sciences2020
Posterior reversible encephalopathy syndrome in patients with COVID-19.
Article in Journal of the neurological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 5 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Neurological manifestations of COVID-19: a systematic review and detailed comprehension.The International journal of neuroscience · 2023Pooled it
- Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome in patients with COVID-19 infection: is there a link? A systematic review and case report analysis.Journal of neurology · 2023Pooled it
- Brain MRI findings in COVID-19 patients with PRES: A systematic review.Clinical imaging · 2022Pooled it
- Status epilepticus and COVID-19: A systematic review.Epilepsy & behavior : E&B · 2021Pooled it
- Heterogeneity in Regional Damage Detected by Neuroimaging and Neuropathological Studies in Older Adults With COVID-19: A Cognitive-Neuroscience Systematic Review to Inform the Long-Term Impact of the Virus on Neurocognitive Trajectories.Frontiers in aging neuroscience · 2021Pooled it
- Superinfected COVID-19 in a young patient with posterior reversible encephalopathy syndrome: A case report.Clinical case reports · 2024Article
- [COVID-19: Neurological manifestations and complications during the acute phase of the disease].Bulletin de l'Academie nationale de medecine · 2023Review
- Posterior reversible encephalopathy syndrome in SARS-CoV-2 infection: A case report and review of literature.Clinical case reports · 2023Article
- Posterior reversible encephalopathy syndrome on COVID-19.Radiology case reports · 2022Article
- A Case Report of Posterior Reversible Encephalopathy Syndrome (PRES) in a Nonsevere Case of COVID-19.Brain sciences · 2022Article
- Neurological Manifestations in Pediatric Patients Hospitalized for COVID-19: Experiences of the National Medical Center "20 de Noviembre" in Mexico City.Children (Basel, Switzerland) · 2022Article
- Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination.Circulation research · 2022Review
- Stroke Treatment in the Era of COVID-19: a Review.Current treatment options in neurology · 2022Review
- Asymmetric posterior reversible encephalopathy syndrome secondary to epilepsy occurring in the chronic phase of subarachnoid hemorrhage.Surgical neurology international · 2022Article
- The association of posterior reversible encephalopathy syndrome with COVID-19: A systematic review.Annals of medicine and surgery (2012) · 2021Review
- Quantitative Analysis of the Olfactory System in COVID-19: An MR Imaging Study.AJNR. American journal of neuroradiology · 2021Article
- A little consideration for "Rare presentations of COVID-19: PRES-like leukoencephalopathy and carotid thrombosis".Clinical imaging · 2021Article
- Neurological complications and infection mechanism of SARS-COV-2.Signal transduction and targeted therapy · 2021Review
- A broad spectrum of posterior reversible encephalopathy syndrome - a case series with clinical and paraclinical characterisation, and histopathological findings.BMC neurology · 2021Article
- Response to correspondence concerning "Posterior reversible encephalopathy syndrome (PRES) associated with COVID-19".Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo report four patients with coronavirus disease 2019 (COVID-19) who developed posterior reversible encephalopathy syndrome (PRES).
methodsPatient data was abstracted from medical records at Weill Cornell Medical Center.
resultsFour patients with SARS-CoV-2 infection and PRES were identified. The patients' ages ranged from 64 to 74 years, and two were women. All four patients were admitted to the hospital with acute respiratory distress syndrome requiring intensive care unit admission and mechanical ventilation. PRES was diagnosed after persistent confusion, lethargy, new focal neurological deficits, or seizures were noted, with evidence of seizures on electroencephalogram for two of the patients. Imaging confirmed the presence of cerebral vasogenic edema. All four patients had elevated blood pressure and renal injury in the days preceding PRES diagnosis, as well as evidence of systemic inflammation and systemic hypercoagulability. Symptoms of PRES improved with blood pressure control.
conclusionsOur four cases demonstrate the occurrence of PRES in critically-ill patients with COVID-19. PRES should be considered in the differential for acute neurological deficits and seizures in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.